May 5, 2023 07:45 AM EDTUpdated 12:24 PM
Financing
Startups

Ace­lyrin's IPO is an 'N of 1', in­dus­try in­sid­ers say, as 50+ biotechs are still wait­ing for their mo­ment on the mar­kets

Kyle LaHucik

Biotech Correspondent

Cal­i­for­nia drug de­vel­op­er Ace­lyrin land­ed on the Nas­daq Fri­day morn­ing in one of the largest biotech de­buts since 2021, at

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

As­traZeneca de­tails its oral SERD 'switch­ing' reg­i­men as fea­si­bil­i­ty ques­tions re­main

Take­da, Pro­tag­o­nist un­veil ple­nary da­ta for po­ten­tial block­buster rare blood dis­ease drug

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

As life-sav­ing check­point drugs move to ear­li­er can­cers, re­searchers de­bate how best to use them

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times